Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dexanabinol: Phase II

PARS said that in a 33-patient Phase II study, intravenous administration of 200 mg

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE